

RESEARCH ARTICLE

Calcium chloride enhances the delivery of exosomes

Hyeon Kim^{1,2}, Ji-Young Kang¹, Dasom Mun^{1,2}, Nuri Yun^{3†*}, Boyoung Joung^{1,2†*}

1 Division of Cardiology, Yonsei University College of Medicine, Seoul, Republic of Korea, **2** Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul, Republic of Korea, **3** Institute of Life Science & Biotechnology Yonsei University, Seoul, Republic of Korea

† Joint senior authors.

* cby6908@yuhs.ac (BYJ); yunnuri@hanmail.net (NRY)

OPEN ACCESS

Citation: Kim H, Kang J-Y, Mun D, Yun N, Joung B (2019) Calcium chloride enhances the delivery of exosomes. PLoS ONE 14(7): e0220036. <https://doi.org/10.1371/journal.pone.0220036>

Editor: Amitava Mukherjee, VIT University, INDIA

Received: January 30, 2019

Accepted: July 7, 2019

Published: July 22, 2019

Copyright: © 2019 Kim et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: This study was supported by research grants from the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (NRF-2017R1A2B3003303), and from the Korean Healthcare Technology R&D project funded by the Ministry of Health & Welfare (HI16C0058). The funders had no role in study design data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Abstract

Exosomes might have an unimproved potential to serve as effective delivery vehicles. However, when exosomes are developed for therapeutic applications, a method to enhance their delivery is important. This study aimed to evaluate whether calcium chloride (CaCl₂) or other chloride compounds could enhance exosome delivery to various cells without causing toxicity. Exosomes were purified from human serum by using the ExoQuick exosome precipitation kit. Isolated exosomes were mixed with CaCl₂ at concentrations ranging from 100 μM to 1 mM, and then washed using Amicon filter for treating the cells. The delivery efficiency of exosomes and the viability of the cells [HEK 293 (human kidney cells) and H9C2 (rat cardiomyocytes)] were evaluated. Cellular uptake of exosomes was observed using a confocal microscope based on PKH26 labeling of exosomes. CaCl₂ increased the delivery of exosomes in a dose- and treatment time-dependent manner. In HEK 293 cells, a CaCl₂ concentration of 400 μM and exposure time of 12 h increased the delivery of exosomes by >20 times compared with controls. In H9C2 cells, a CaCl₂ concentration of 400 μM and exposure time of >24 h increased the delivery of exosomes by >400 times compared with controls. The viability of both cell lines was maintained up to a CaCl₂ concentration of 1 mM. However, cobalt chloride, cupric chloride, and magnesium chloride did not change the delivery of exosomes in both cell lines. These results suggest that the use of CaCl₂ treatment might be a useful method for enhancing the delivery of exosomes.

Introduction

Exosomes are 40–200nm vesicles secreted by many types of cells [1]. They exist in cell culture medium and in numerous body fluids including plasma and serum [2]. The biogenesis of exosomes involves the fusion of multivesicular bodies enclosing pools of endosomal vesicles with the cell plasma membrane and the subsequent release of the vesicles into intercellular space [3]. These vesicles are known to carry a variety of signaling molecules, including nucleic acids, predominantly mRNA and microRNA, functional proteins, and lipids [4]. Owing to their outstanding cell-to-cell communication characteristic, numerous studies have investigated the

role of exosomes in physiological and pathophysiological processes, including immune modulation [5,6], tumor metastasis [7], and neurodegenerative diseases [8,9].

Many studies have suggested that exosomes can be ideal candidates for use as carriers for drug delivery [10,11]. Exosomes have been used as delivery vehicles of small nucleic acids such as micro-RNAs and small interfering RNAs or low-molecular-weight medicines [12,13]. Exosome-liposome hybrid nanoparticles can deliver the CRISPR-Cas9 system in mesenchymal stem cells, and thus can be promising tools in *in vivo* gene manipulation [14]. The organ-specific delivery of exosomes was improved by expressing target peptides with Lamp2 on the surface of exosomes [12,15–17]. Pseudotyping exosomes have been suggested as vehicles for the enhanced delivery of protein reporters and protein therapeutics to target cells [18]. However, a simpler method for enhancing the delivery efficacy of exosomes is needed [19].

To date, calcium chloride (CaCl₂)-associated transfection methods have been widely used to introduce DNA into mammalian cells, with relatively low cost and low toxicity [20]. However, whether CaCl₂ can increase the delivery efficiency of exosomes to the target cells has not been evaluated. In a recent study, CaCl₂ and subsequent heat shock-mediated miR-15a-loaded exosomes showed higher delivery of miR-15a to target cells than miR-15a-electroporated exosome [21]. Taken together, we hypothesized that CaCl₂ or other chloride compounds can affect the delivery efficacy of exosomes into target cells.

Thus, we aimed to investigate whether exosomes mixed with CaCl₂ can show improved delivery to cells compared with normal exosomes, thus providing an effective method for drug delivery in the future.

Materials and methods

Exosome purification and labeling

Human peripheral blood samples from non-atrial fibrillation patients were obtained at Yonsei University Health System (Seoul, Korea). The study protocol conformed to the principles outlined in Declaration of Helsinki, and was approved by the local ethics committee (YUMC 4-2011-0872). Informed consent was obtained from all patients. The name of ethics committee is as follows: Severance Hospital.

Exosomes were purified using the ExoQuick exosome precipitation kit (SBI System Bioscience, Mountain View, CA, USA), according to manufacturer's instructions. A 250 μ L volume of human serum was mixed with 63 μ L ExoQuick solution and incubated overnight at 4°C. After centrifugation (1500g for 30 min), the supernatant was discarded and tubes were centrifuged again (1500g for 5 min). All traces of fluid were aspirated, then pellets were resuspended in 200 μ L phosphate-buffered saline (PBS) [22].

After exosome treatment to cells, the uptake of exosomes by cultured HEK 293 cells (human kidney cells) and H9C2 cells (rat cardiomyocytes) was assessed using a confocal microscope (LSM710; Carl Zeiss GmbH, Jena, Germany). For this evaluation, purified exosomes were labeled using PKH26 dye (Sigma, Germany) according to the manufacturer's instructions, as described previously [23]. Briefly, exosomes were suspended in 1 mL diluent C containing 5 μ M PKH26 and incubated for 5 min. The labeling action was stopped by incubating for 1 min with an equal volume of 1% bovine serum albumin (Bovogen, Melbourne, Australia). The exosomes were washed twice with Amicon ultrafilter (10 KDa cut-off, Millipore, MA, USA) with cold PBS. Thereafter, the exosomes were resuspended in 200 μ L PBS.

Mixture of exosomes and CaCl₂

To deliver exosomes efficiently to cells, a modified method of CaCl₂ transfection was developed. PKH26-labeled exosomes (50 μ g in PBS) were mixed with CaCl₂ solution (0.2 M stock).

The final volume was adjusted to 150 μ L using sterile PBS. The mixture was incubated at 37°C in a shaker for 10 min at 25 rpm, and then the tube was immediately placed on ice. The Exo-Quick reagent (30 μ L) was added, and the mixture was placed on ice for 30 min. The sample was centrifuged for 3 min at 13,000–14,000 rpm in a microfuge. The supernatant was removed, and the mixture pellet was resuspended in 1 mL PBS. The pellet was washed using Amicon Ultra tubes with cold PBS. Thereafter, the exosomes were resuspended in 200 μ L PBS.

Western blot analysis

Western blot analysis was performed as we described previously [16]. Briefly, ultracentrifuged exosomal pellets were lysed with radioimmunoprecipitation buffer (ATTO, NY, USA) containing a protease inhibitor cocktail (ATTO). The total amount of protein was determined using a 660-nm protein assay (Pierce, MA, USA), and equal amounts (20 μ g) of exosomal proteins were resolved using sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes. The blots were probed overnight at 4°C with anti-Lamp2 (SC-18822; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-CD81 (SC-166029, Santa Cruz Biotechnology), or anti-Alix (SC-99010, Santa Cruz Biotechnology), as indicated. The membranes were then exposed to horseradish peroxidase-conjugated mouse or rabbit anti-mouse secondary antibodies (Santa Cruz Biotechnology), and the results were visualized using chemiluminescence (Advansta, Menlo Park, CA, USA).

Transmission electron microscopy

A Formvar-carbon-coated electron microscope grid was placed with the formvar side down on top of an exosome drop for approximately 1 min. The grid was removed, blotted with filter paper, and placed onto a drop of 2% uranyl acetate for 15 s. The excess uranyl acetate was removed, and the electron microscope grid was examined and photographed for transmission electron microscopy (TEM). All thin sections were observed under a transmission electron microscope (JEM-1011; JEOL, Tokyo, Japan) at an acceleration voltage of 80 kV. Images were captured with a side-mounted Camera-Megaview III (Soft Imaging System, Münster, Germany) [24].

Nanoparticle tracking analysis

The number of nanoparticles in serum-derived exosomes was assessed using the Nanosight LM10-HS nanoparticle characterization system (Nanosight Ltd., Amesbury, UK). Three recordings were performed for each sample. The Nanosight Tracking Analysis 3.2 software was then used to analyze the video, and to determine the particle concentration and the size distribution of the particles. Three videos of 10-s duration were recorded for each sample.

Cell culture

HEK 293 cells and H9C2 cells were cultivated as we described previously [16]. Briefly, HEK 293 cells (Korean Cell Line Bank, Seoul, Korea) and H9C2 cells (American Type Culture Collection, Manassas, VA, USA) were maintained in Dulbecco's modified Eagle's medium (Welgene, Daegu, Korea) containing 10% fetal bovine serum (Young In Frontier, Seoul, Korea) and 1% penicillin-streptomycin (Gibco, NY, USA). Cells were cultured in a humidified incubator at 37°C with 5% CO₂.

Immunocytochemistry and confocal microscopy

Immunocytochemistry and confocal microscopy were executed as we described previously [16]. After treating HEK 293 and H9C2 cells with or without exosomes for 24 h, the cells were fixed with 4% paraformaldehyde for 60 min at room temperature and washed with PBS. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (Santa Cruz Biotechnology). Fluorescence images were obtained using a Zeiss LSM710 confocal microscope with 2 excitation filters (405 and 543 nm). The data were recorded as serial optical sections, each consisting of 1024×1024 pixels, overlaid to distinguish between the separate emission channels, and saved as TIFF (tagged image file format) files. Quantification was performed using Image J program. PKH26 expression and DAPI expression were measured respectively using the RGB function of histogram. The same slide was averaged by taking three different parts, and the number of samples was three.

Cell proliferation assay

The cytotoxic potential of exosomes was assessed using an MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] assay (Promega, Madison, WI, USA). HEK 293 cells were treated with exosomes in triplicate in a 96-well plate. Cell survival was determined using an enzyme-linked immunosorbent assay plate reader (Molecular Devices, Menlo Park, CA, USA).

Mouse and NIRF imaging

Male C57BL/6 mice (25 g) were purchased from Orient Bio (Seoul, Korea). All animal experiments were approved by the Institutional Animal Care and Use Committee of Yonsei University College of Medicine (Seoul, Korea), and were conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. We injected 150 μg of PKH26 labeled exosomes per animal. After 24 h, the heart, liver, and spleen of each mouse were harvested and IVIS Spectrum imaging system (PerkinElmer, Waltham, MA, USA) was employed to capture Near-infrared fluorescence (NIRF) images. PKH26-related fluorescence signals were discriminated from the auto-fluorescence signals using Living Image software (PerkinElmer).

Statistical analysis

Data analyses were performed with Student's t-test between two groups. A p-value of <0.05 was considered statistically significant. All statistical analyses were conducted with SPSS version 23.0 statistical package (SPSS Inc., Chicago, IL, USA).

Results

Isolation and characterization of serum exosomes

The protocol of preparing the mixture of exosomes and CaCl_2 is shown in Fig 1A. CaCl_2 -associated transfection methods are widely used for introducing DNA into mammalian cells [20]. We used a modified protocol in which incubation at 37°C in a shaker was performed to increase exosome delivery to cells. Exosomes were isolated from peripheral blood by using the ExoQuick reagent, as described in Materials and Methods. The profiles of serum-derived exosomes were characterized using nanoparticle tracking analysis, TEM, and western blotting. According to the Nanosight instrument, the mean particle diameter was 136.6 nm, and mean concentration was 8.59×10^7 particles/ml (Fig 1B). And structurally intact exosomes were detected by TEM analysis (Fig 1C). There was no significant difference in the size and




Fig 1. Characterization of exosomes. (A) Study protocol. (B) Nanoparticle tracking analysis of exosomes showing the number and size distribution of particles. (C) Representative electron microscopic image of the exosomes (scale bar, 40 nm). (D) Western blot analysis of isolated exosomes and cell lysate.

<https://doi.org/10.1371/journal.pone.0220036.g001>

concentration of exosomes before and after addition of CaCl₂ when TEM and NTA were compared (S1 Fig). When cell lysate and exosome were examined by western blot analysis, the exosomes were positive for exosomal markers including Alix, CD81, and Lamp2 (Fig 1D). Taken together, the exosomes were successfully purified.

CaCl₂ dose-dependent delivery of exosomes to HEK 293 and H9C2 cells

To identify whether CaCl₂ treatment improves delivery of exosomes, we added several concentrations of CaCl₂ to exosomes and these mixtures were incubated at 37°C in a shaker. The mixture of exosomes and CaCl₂ was used to treat the HEK 293 and H9C2 cells, which were then incubated for 24 h. The most commonly used method for monitoring exosome uptake is to stain exosomal membranes with fluorescent lipid membrane dyes such as PKH26 [25], PKH67 [26], and DiI [27]. In this study, PKH26 was used to label the exosomes and to monitor the uptake of labeled exosomes by cells. The uptake of labeled exosomes by cells was confirmed using a confocal microscope (Fig 2A).




Fig 2. Delivery efficiency of exosomes with CaCl₂ in a dose-dependent manner. (A) Typical example of delivery of exosomes to HEK 293 cells (left panels) and H9C2 cells (right panels). (B) and (C) Delivery efficiency and cell viability of exosomes labeled with PKH26 (red) at different concentrations of CaCl₂ in HEK 293 (B) and H9C2 (C) cells. Fluorescent microscopic images (left panels), and fluorescence intensity and cell viability (right panels). The data are presented as the mean ± s.e.m. *P < 0.01.

<https://doi.org/10.1371/journal.pone.0220036.g002>

In HEK 293 cells, the delivery of exosomes was dose-dependently increased. At a CaCl₂ concentration of 400 μM (P < 0.001), the delivery of exosomes increased the most, and then reached a plateau. In H9C2 cells, the delivery of exosomes was significantly increased over 400 times (P = 0.003) at a CaCl₂ concentration of 200 μM. After peaking at 400 μM, it decreased at higher concentrations (P < 0.001).

In order for exosomes to be used as therapeutic application, there should be no damage to the cells. Thus, we checked cell viability after exosomes incubation. Cell viability was maintained up to a CaCl₂ concentration of 1 mM in both cells (Fig 2B and 2C). As a result, we found that the CaCl₂ treatment improved the delivery of exosomes to cells without toxicity.

Optimal time for exosome uptake by cells

Because 400 μM was the CaCl_2 concentration with the maximum delivery of exosomes, we evaluated the cellular uptake of exosomes at different durations of exposure to these CaCl_2 -treated exosomes. In HEK 293 cells, the cellular uptake of exosomes increased as the incubation time increased, with saturation at around 12 h and a decrease after 24 h (Fig 3A, $P < 0.0001$). In H9C2 cells, the uptake increased as the incubation time increased, with saturation at around 24 h and a decrease after 48 h (Fig 3B, $P < 0.0001$). Taken together, we found the most efficient concentration of CaCl_2 and the appropriate treatment time.

CaCl_2 is more effective than other chloride compounds

Next, we assessed whether the cellular uptake of exosomes will be increased by other chloride compounds. Cobalt chloride (CoCl_2), magnesium chloride (MgCl_2) and cupric chloride (CuCl_2) were treated exosome at a concentration of 400 μM for 24 hours. Exosome delivery and cell viability were measured by the above method. In HEK 293 cells, the cellular delivery of exosomes was not significantly improved by CoCl_2 or MgCl_2 , but was rather decreased by CuCl_2 (Fig 4A). In H9C2 cells, the cellular delivery of exosomes was improved by CoCl_2 ($P = 0.017$) and MgCl_2 ($P = 0.004$), but not by CuCl_2 (Fig 4B). Moreover, the cell viability was significantly decreased by MgCl_2 in both cell lines. These results show that CaCl_2 significantly enhances intracellular delivery of exosomes compared to other chloride compounds.




Fig 3. Delivery efficiency of exosomes with CaCl_2 in a time-dependent manner. (A) and (B) Delivery efficiency of exosomes labeled with PKH26 (red) at different time exposures to CaCl_2 -treated exosomes in HEK 293 (A) and H9C2 (B) cells. Fluorescent microscopic images (upper panels) and fluorescence intensity (lower panels). * $P < 0.01$.

<https://doi.org/10.1371/journal.pone.0220036.g003>




Fig 4. Delivery efficiency of exosomes with chloride compounds. (A, C) Delivery efficiency and (B, D) cell viability of exosomes labeled with PKH26 (red) added with different chloride compounds in HEK 293 (A,B) and H9C2 (C,D) cells. Fluorescent microscopic images (upper panels), and fluorescence intensity and cell viability (lower panels). *P < 0.01.

<https://doi.org/10.1371/journal.pone.0220036.g004>

In vivo delivery of CaCl₂-treated exosomes

We also performed *in vivo* experiments to support the claim that CaCl₂ enhances the delivery of exosomes. Exosomes were injected via tail vein in mice and sacrificed 24 hours later. The level of PKH26 was measured using In Vivo Imaging System (IVIS) of organs. We confirmed

that CaCl₂-treated exosomes significantly increased the delivery in heart, lung, kidney, and spleen (S3 Fig). Based on these results, we suggest that CaCl₂-treated exosomes allow higher delivery than normal exosomes *in vivo*.

Discussion

In this study, we attempted to enhance the delivery efficiency of exosomes by using CaCl₂, which is commonly used for transfection of DNA into mammalian cells. Exosomes incubated with CaCl₂ increased delivery efficiency in a dose-dependent manner in HEK 293 and H9C2 cells. The optimum duration of treatment with exosomes added with CaCl₂ was 12 h for HEK 293 cells and 24 h for H9C2 cells. Finally, it was confirmed that CaCl₂ significantly increased the intracellular uptake of exosomes when compared with other chloride compounds at the same concentration. On the basis of these results, we suggest that adding CaCl₂ to exosomes for treating the cells is an efficient method of increasing the delivery of exosomes.

Exosomes are vesicles of endocytic origin released by many cells [28]. They are crucial in distant cell-cell communication because they can enter the circulatory system when they are secreted and can pass through additional biological barriers [29]. R. Liu et al. recent accumulated evidence suggests that these nano-sized vesicles can deliver various RNAs into cells from the natural pathway, to deliver genetic material in organisms [30]. As exosomes are promising for use as vectors in clinical applications owing to their strong biocompatibility, enhancement of exosome delivery is an important research topic [31]. One of the limitations of exosomes is the requirement for high capacity production for clinical use [19,32]. Our findings provide a solution to this limitation.

In the standard method for transforming of *Escherichia coli* with external DNA, cells are known to be suitable for DNA uptake by incubating in ice-cold 100 mM CaCl₂ [33]. CaCl₂ assists the interactions between DNA molecules and the cell surface and helps endocytosis of the DNA molecules [34]. We modified this protocol to increase the uptake of exosomes into cells. Also, calcium influx induces endocytosis and exocytosis, and is known to trigger vesicle fusion [35–37]. Therefore, we anticipate that the addition of CaCl₂ increases the efficiency of exosome delivery. However, more research is needed to confirm these mechanisms. In our study, up to 1 mM CaCl₂ was used, but no cytotoxicity was observed. Moreover, CaCl₂ is a common compound used in various research institutes. In this experiment, a low CaCl₂ concentration was used, thus providing the advantages of low cost and high accessibility. We also compared CaCl₂ with other chloride compounds. Our results showed that CaCl₂ was the only common enhancer of exosome delivery between HEK 293 and H9C2 cells. Our findings provide useful technological insights for the development of exosome-mediated drug delivery.

Supporting information

S1 Fig. Characterization of CaCl₂-Exo. (A) Representative electron microscopic image of CaCl₂-Exo (scale bar, 40 nm). (B) Size distribution of CaCl₂-Exo measured from TEM images. (C) Nanoparticle tracking analysis of CaCl₂-Exo showing the concentration of particles. (TIF)

S2 Fig. Un-cropped Western blots from main Fig 1. (TIF)

S3 Fig. *In vivo* delivery of exosomes and CaCl₂-Exo. (A) Representative NIRF images (overlaid with photograph) of mice organs which received administration of PBS, PKH26-labeled exosomes, or CaCl₂-Exo. (B) Quantitation of fluorescence intensity in the lesion region.

* $P < 0.05$.
(TIF)

Author Contributions

Conceptualization: Hyoeun Kim, Nuri Yun.

Data curation: Hyoeun Kim, Ji-Young Kang.

Formal analysis: Hyoeun Kim, Ji-Young Kang.

Funding acquisition: Boyoung Joung.

Investigation: Hyoeun Kim.

Methodology: Hyoeun Kim, Ji-Young Kang.

Project administration: Nuri Yun, Boyoung Joung.

Resources: Hyoeun Kim, Ji-Young Kang, Dasom Mun.

Software: Hyoeun Kim.

Supervision: Nuri Yun, Boyoung Joung.

Validation: Hyoeun Kim, Ji-Young Kang, Dasom Mun.

Visualization: Hyoeun Kim.

Writing – original draft: Hyoeun Kim.

Writing – review & editing: Nuri Yun, Boyoung Joung.

References

1. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. *Nat Rev Immunol*. 2009; 9: 581–593. <https://doi.org/10.1038/nri2567> PMID: 19498381
2. Ashcroft BA, de Sonnevile J, Yuana Y, Osanto S, Bertina R, Kuil ME, et al. Determination of the size distribution of blood microparticles directly in plasma using atomic force microscopy and microfluidics. *Biomed Microdevices*. 2012; 14: 641–649. <https://doi.org/10.1007/s10544-012-9642-y> PMID: 22391880
3. Kowal J, Tkach M, Thery C. Biogenesis and secretion of exosomes. *Curr Opin Cell Biol*. 2014; 29: 116–125. <https://doi.org/10.1016/j.ceb.2014.05.004> PMID: 24959705
4. Li D, Liu J, Guo B, Liang C, Dang L, Lu C, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation. *Nat Commun*. 2016; 7: 10872. <https://doi.org/10.1038/ncomms10872> PMID: 26947250
5. Caradec J, Kharmate G, Hosseini-Beheshti E, Adomat H, Gleave M, Guns E. Reproducibility and efficiency of serum-derived exosome extraction methods. *Clin Biochem*. 2014; 47: 1286–1292. <https://doi.org/10.1016/j.clinbiochem.2014.06.011> PMID: 24956264
6. Kimura K, Hohjoh H, Fukuoka M, Sato W, Oki S, Tomi C, et al. Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. *Nat Commun*. 2018; 9: 17. <https://doi.org/10.1038/s41467-017-02406-2> PMID: 29295981
7. Plebanek MP, Angeloni NL, Vinokour E, Li J, Henkin A, Martinez-Marin D, et al. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche. *Nat Commun*. 2017; 8: 1319. <https://doi.org/10.1038/s41467-017-01433-3> PMID: 29105655
8. Gui Y, Liu H, Zhang L, Lv W, Hu X. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease. *Oncotarget*. 2015; 6: 37043–37053. <https://doi.org/10.18632/oncotarget.6158> PMID: 26497684
9. Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. *J Biol Chem*. 2012; 287: 3842–3849. <https://doi.org/10.1074/jbc.M111.277061> PMID: 22057275

10. Batrakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. *J Control Release*. 2015; 219: 396–405. <https://doi.org/10.1016/j.jconrel.2015.07.030> PMID: 26241750
11. Bellavia D, Raimondi L, Costa V, De Luca A, Carina V, Maglio M, et al. Engineered exosomes: A new promise for the management of musculoskeletal diseases. *Biochim Biophys Acta Gen Subj*. 2018; 1862: 1893–1901. <https://doi.org/10.1016/j.bbagen.2018.06.003> PMID: 29885361
12. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakkhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. *Nat Biotechnol*. 2011; 29: 341–345. <https://doi.org/10.1038/nbt.1807> PMID: 21423189
13. Tian Y, Li S, Song J, Ji T, Zhu M, Anderson GJ, et al. A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. *Biomaterials*. 2014; 35: 2383–2390. <https://doi.org/10.1016/j.biomaterials.2013.11.083> PMID: 24345736
14. Lin Y, Wu J, Gu W, Huang Y, Tong Z, Huang L, et al. Exosome-Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCs. *Adv Sci (Weinh)*. 2018; 5: 1700611. <https://doi.org/10.1002/adv.201700611> PMID: 29721412
15. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. *Int J Nanomedicine*. 2012; 7: 1525–1541. <https://doi.org/10.2147/IJN.S29661> PMID: 22619510
16. Kim H, Yun N, Mun D, Kang JY, Lee SH, Park H, et al. Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomes. *Biochem Biophys Res Commun*. 2018; 499: 803–808. <https://doi.org/10.1016/j.bbrc.2018.03.227> PMID: 29621543
17. Bellavia D, Raimondo S, Calabrese G, Forte S, Cristaldi M, Patinella A, et al. Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth. *Theranostics*. 2017; 7: 1333–1345. <https://doi.org/10.7150/thno.17092> PMID: 28435469
18. Meyer C, Losacco J, Stickney Z, Li L, Marriott G, Lu B. Pseudotyping exosomes for enhanced protein delivery in mammalian cells. *Int J Nanomedicine*. 2017; 12: 3153–3170. <https://doi.org/10.2147/IJN.S133430> PMID: 28458537
19. Yamashita T, Takahashi Y, Takakura Y. Possibility of Exosome-Based Therapeutics and Challenges in Production of Exosomes Eligible for Therapeutic Application. *Biol Pharm Bull*. 2018; 41: 835–842. <https://doi.org/10.1248/bpb.b18-00133> PMID: 29863072
20. Kingston RE, Chen CA, Rose JK. Calcium phosphate transfection. *Curr Protoc Mol Biol*. 2003;Chapter 9: Unit 9.1. <https://doi.org/10.1002/0471142727.mb0901s63> PMID: 18265332
21. Zhang D, Lee H, Zhu Z, Minhas JK, Jin Y. Enrichment of selective miRNAs in exosomes and delivery of exosomal miRNAs in vitro and in vivo. *Am J Physiol Lung Cell Mol Physiol*. 2017; 312: L110–L121. <https://doi.org/10.1152/ajplung.00423.2016> PMID: 27881406
22. Wang M, Qiu R, Yu S, Xu X, Li G, Gu R, et al. Paclitaxel-resistant gastric cancer MGC803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-1555p. *Int J Oncol*. 2019; 54: 326–338. <https://doi.org/10.3892/ijo.2018.4601> PMID: 30365045
23. Saeed-Zidane M, Linden L, Salilew-Wondim D, Held E, Neuhoff C, Tholen E, et al. Cellular and exosome mediated molecular defense mechanism in bovine granulosa cells exposed to oxidative stress. *PLoS One*. 2017; 12: e0187569. <https://doi.org/10.1371/journal.pone.0187569> PMID: 29117219
24. Kim SY, Kim HJ, Kim HJ, Kim DH, Han JH, Byeon HK, et al. HSPA5 negatively regulates lysosomal activity through ubiquitination of MUL1 in head and neck cancer. *Autophagy*. 2018; 14: 385–403. <https://doi.org/10.1080/15548627.2017.1414126> PMID: 29260979
25. Muller L, Simms P, Hong CS, Nishimura MI, Jackson EK, Watkins SC, et al. Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. *Oncoimmunology*. 2017; 6: e1261243. <https://doi.org/10.1080/2162402X.2016.1261243> PMID: 28919985
26. Wei F, Ma C, Zhou T, Dong X, Luo Q, Geng L, et al. Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p. *Mol Cancer*. 2017; 16: 132. <https://doi.org/10.1186/s12943-017-0694-8> PMID: 28743280
27. Zhang Z, Yang J, Yan W, Li Y, Shen Z, Asahara T. Pretreatment of Cardiac Stem Cells With Exosomes Derived From Mesenchymal Stem Cells Enhances Myocardial Repair. *J Am Heart Assoc*. 2016;5. <https://doi.org/10.1161/jaha.115.002856> PMID: 26811168
28. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol*. 2007; 9: 654–659. <https://doi.org/10.1038/ncb1596> PMID: 17486113
29. Jiang XC, Gao JQ. Exosomes as novel bio-carriers for gene and drug delivery. *Int J Pharm*. 2017; 521: 167–175. <https://doi.org/10.1016/j.ijpharm.2017.02.038> PMID: 28216464

30. Liu R, Liu J, Ji X, Liu Y. Synthetic nucleic acids delivered by exosomes: a potential therapeutic for gene-related metabolic brain diseases. *Metab Brain Dis.* 2013; 28: 551–562. <https://doi.org/10.1007/s11011-013-9434-y> PMID: 24022398
31. Luan X, Sansanaphongpricha K, Myers I, Chen H, Yuan H, Sun D. Engineering exosomes as refined biological nanoplateforms for drug delivery. *Acta Pharmacol Sin.* 2017; 38: 754–763. <https://doi.org/10.1038/aps.2017.12> PMID: 28392567
32. van der Meel R, Fens MH, Vader P, van Solinge WW, Eniola-Adefeso O, Schiffelers RM. Extracellular vesicles as drug delivery systems: lessons from the liposome field. *J Control Release.* 2014; 195: 72–85. <https://doi.org/10.1016/j.jconrel.2014.07.049> PMID: 25094032
33. Aich P, Patra M, Chatterjee AK, Roy SS, Basu T. Calcium chloride made *E. coli* competent for uptake of extraneous DNA through overproduction of OmpC protein. *Protein J.* 2012; 31: 366–373. <https://doi.org/10.1007/s10930-012-9411-z> PMID: 22562126
34. Wigler M, Silverstein S, Lee LS, Pellicer A, Cheng Y, Axel R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. *Cell.* 1977; 11: 223–232 [https://doi.org/10.1016/0092-8674\(77\)90333-6](https://doi.org/10.1016/0092-8674(77)90333-6) PMID: 194704
35. Wu XS, McNeil BD, Xu J, Fan J, Xue L, Melicoff E, et al. Ca²⁺ and calmodulin initiate all forms of endocytosis during depolarization at a nerve terminal. *Nat Neurosci.* 2009; 12: 1003–1010. <https://doi.org/10.1038/nn.2355> PMID: 19633667
36. Lariccia V, Fine M, Magi S, Lin MJ, Yaradanakul A, Llaguno MC, et al. Massive calcium-activated endocytosis without involvement of classical endocytic proteins. *J Gen Physiol.* 2011; 137: 111–132. <https://doi.org/10.1085/jgp.201010468> PMID: 21187336
37. Kyoung M, Zhang Y, Diao J, Chu S, Brunger AT. Studying calcium-triggered vesicle fusion in a single vesicle-vesicle content and lipid-mixing system. *Nat Protoc.* 2013; 8: 1–16. <https://doi.org/10.1038/nprot.2012.134> PMID: 23222454